BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.
BRCA1
BRCA2
Combination
Cytoreduction surgical procedures
Drug therapy
Genes
Neoadjuvant therapy
Ovarian neoplasms
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
15
04
2020
revised:
29
08
2020
accepted:
09
10
2020
pubmed:
3
11
2020
medline:
23
1
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
In advanced ovarian cancer (AOC) the complete eradication of all macroscopic disease at primary debulking surgery (PDS) is associated with the best outcome. If this cannot be achieved, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) can make complete cytoreduction possible while reducing postoperative morbidity. It is still debated if PDS and NACT- IDS are associated with similar survival and if they provide different outcomes when optimal cytoreduction is achieved. For a tailored surgical planning, accurate prediction of tumor's resectability, assessment of patient's performance status and in-depth knowledge of tumor biology are required. Both BRCA1/2 status and the "chemotherapy response score" are reliable markers of chemosensitivity and may thus improve our way to triage patients to PDS or NACT-IDS; furthermore, they could be used to modulate our surgical approach and define appropriate subgroups of patients for whom new therapies should be tested.
Identifiants
pubmed: 33137578
pii: S1040-8428(20)30264-X
doi: 10.1016/j.critrevonc.2020.103128
pii:
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103128Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.